Summary:

Summary:

Summary

Summary

Article currently in progress (1/17/23) Summary: ASCO-GI starts this Thursday, January 19, 2023 This conference focuses on indications including stomach cancer, gastrointestinal cancer, esophageal cancer, and colorectal cancer ( https://conferences.asco.org/gi/program ) In past years, big readouts have happened at this conference including from several Phase 3 trials On Thursday Jan 19 there is also a PDUFA for a GI indication: the SGEN and MRK PDUFA for Tukysa (Tucatinib) to

(Originally posted 7/25/2022, updated 7/27/22) Summary BPIQ monitors mergers and acquisitions (M&A's) of smid-cap biopharmas Acquisition...